Nine has hit back at a class action by Indigenous Australians who say the broadcaster’s coverage of a $30 million class action settlement with the Queensland government for alleged police misconduct during the 2004 Palm Island riots was discriminatory and inaccurate, saying it reported the events “fairly and accurately”.
Toyota could owe close to $2 billion in compensation to 260,000 car owners after a judge found that diesel filters installed in its Hilux, Fortuner and Prado models were defective and that the cars were sold for more than they were worth.
The trustee of Mayfair Group’s collapsed IPO Wealth Fund has reached an in-principle settlement in a class action alleging it misled investors, who lost $86 million when the fund was wound up.
A judge has barked at lawyers for Nine and a barrister who sued the media company for defamation over its coverage of her battle for custody of famed social media pooch Oscar the cavoodle, saying their “nonsense” quibbling was making him “cranky”.
A judge has hit Westpac with a $1.5 million penalty for misleading 141 customers into believing they had purchased add-on insurance.
The High Court has rejected a special leave application by consumer goods giant Reckitt-Benckiser in its long-running battle with the maker of painkiller Maxigesic.
Insurance Australia Group is investigating the underwriter behind an allegedly unauthorised trade credit policy issued to Greensill Capital, according to a defence by the insurer in a $43 million case brought by a Credit Suisse supply chain fund left heavily exposed after Greensill’s collapse.
Law firm Russells has won a bid for further security against former clients in a negligence case over its handling of a shareholder suit against iron ore miner Macarthur Minerals.
The maker of the popular Invisalign dental aligners may soon face a cross-claim from competitor SmileDirectClub, which it sued for allegedly misleading consumers about the cost and efficacy of its direct-to-consumer teeth alignment kits.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.